Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Oct 17;24(6):1491-1500.
doi: 10.17305/bb.2024.10527.

Association between serum galectin-3 and chronic obstructive pulmonary disease: A meta-analysis

Xiangyu Zhao  1 , Bo Han  1 , Wentao Tang  2 , Shanshan Ji  2 , Lie Wang  2 , Jinbao Huang  2 , Yizhong Hu  2 , Jie Li  3
Affiliations
Meta-Analysis

Association between serum galectin-3 and chronic obstructive pulmonary disease: A meta-analysis

Xiangyu Zhao et al. Biomol Biomed. .

Abstract

Chronic obstructive pulmonary disease (COPD) is a significant public health issue characterized by progressive and irreversible airflow limitation. The aim of this meta-analysis was to determine the association between changes in serum galectin-3 levels and COPD and to assess the relationship between serum galectin-3 levels and acute exacerbations of COPD (AECOPD). Relevant observational studies were retrieved from electronic databases, including PubMed, Web of Science, Embase, Wanfang, and China National Knowledge Infrastructure (CNKI). A random-effects model was used to combine the data, incorporating the influence of between-study heterogeneity. Twelve case-control studies were included. The pooled results showed a significantly higher serum level of galectin-3 in patients with COPD compared to controls (standardized mean difference [SMD] 0.60; 95% confidence interval [CI] 0.40 - 0.80; P < 0.001; I2 = 68%). Further meta-analysis suggested higher levels of serum galectin-3 in patients with AECOPD compared to those with stable COPD (SMD 0.33; 95% CI 0.20 - 0.46; P < 0.001; I2 = 0%). Subgroup analyses according to the mean age of the participants, the proportion of males, and study quality scores did not significantly change the results (P for subgroup differences all > 0.05). In conclusion, patients with COPD were found to have higher serum levels of galectin-3, with levels further elevated in patients with AECOPD compared to those with stable COPD.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: Authors declare no conflicts of interest.

Figures

Figure 1.
Figure 1.
Flowchart illustrating the process of literature search and study identification. COPD: Chronic obstructive pulmonary disease; Gal-3: Galectin-3.
Figure 2.
Figure 2.
Forest plots for the meta-analysis comparing the serum galectin-3 levels between patients with COPD and healthy controls. COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of COPD; SD: Standard deviation; CI: Confidence interval; Gal-3: Galectin-3.
Figure 3.
Figure 3.
Forest plots for the subgroup analyses comparing the serum galectin-3 levels between patients with COPD and healthy controls. (A) Forest plot illustrating the subgroup analysis based on the disease status; (B) Forest plot illustrating the subgroup analysis based on the mean age of the population. COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of COPD; SD: Standard deviation; CI: Confidence interval; Gal-3: Galectin-3.
Figure 4.
Figure 4.
Forest plots for the subgroup analyses comparing the serum galectin-3 levels between patients with COPD and healthy controls. (A) Forest plot illustrating the subgroup analyses based on the proportion of males; (B) Forest plot illustrating the subgroup analyses based on the study quality scores. COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of COPD; SD: Standard deviation; CI: Confidence interval; Gal-3: Galectin-3.
Figure 5.
Figure 5.
Forest plots for the meta-analysis comparing the serum galectin-3 level between patients with AECOPD and stable COPD. (A) Forest plot illustrating the overall meta-analysis; (B) Forest plot illustrating the subgroup analyses based on the mean ages of the participants; (C) Forest plot illustrating the subgroup analyses based on the proportions of males; (D) Forest plot illustrating the subgroup analyses based on the study quality scores. COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of COPD; SD: Standard deviation; CI: Confidence interval; Gal-3: Galectin-3.
Figure 6.
Figure 6.
Funnel plots for the publication biases underlying the meta-analyses. (A) Funnel plot illustrating the meta-analysis comparing the serum galectin-3 level between patients with COPD and healthy controls; (B) Funnel plot illustrating the meta-analysis comparing the serum galectin-3 level between patients with AECOPD and stable COPD. COPD: Chronic obstructive pulmonary disease; AECOPD: Acute exacerbation of COPD; SMD: Standardized mean difference.
Figure S1.
Figure S1.
The search syntax used in the meta-analysis. COPD: Chronic obstructive pulmonary disease.
See this image and copyright information in PMC

References

    1. Celli BR, Wedzicha JA. Update on clinical aspects of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1257–66. https://doi.org/10.1056/NEJMra1900500. - PubMed
    1. Christenson SA, Smith BM, Bafadhel M, Putcha N. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–42. https://doi.org/10.1016/S0140-6736(22)00470-6. - PubMed
    1. Mah J, Ritchie AI, Finney LJ. Selected updates on chronic obstructive pulmonary disease. Curr Opin Pulm Med. 2024;30(2):136–40. https://doi.org/10.1097/MCP.0000000000001042. - PubMed
    1. Agusti A, Hogg JC. Update on the pathogenesis of chronic obstructive pulmonary disease. N Engl J Med. 2019;381(13):1248–56. https://doi.org/10.1056/NEJMra1900475. - PubMed
    1. Zhang J, Yi Q, Zhou C, Luo Y, Wei H, Ge H, et al. Characteristics, treatments, in-hospital and long-term outcomes among inpatients with acute exacerbation of chronic obstructive pulmonary disease in China: sex differences in a large cohort study. BMC Pulm Med. 2024;24(1):125. https://doi.org/10.1186/s12890-024-02948-4. - PMC - PubMed

Publication types